169 related articles for article (PubMed ID: 15367725)
1. Muscle pain associated with daptomycin.
Veligandla SR; Louie KR; Malesker MA; Smith PW
Ann Pharmacother; 2004 Nov; 38(11):1860-2. PubMed ID: 15367725
[TBL] [Abstract][Full Text] [Related]
2. Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis.
Mergenhagen KA; Pasko MT
Ann Pharmacother; 2007 Sep; 41(9):1531-5. PubMed ID: 17652126
[TBL] [Abstract][Full Text] [Related]
3. Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability.
Golightly LK; Barber GR; Barron MA; Page RL
Drug Metabol Drug Interact; 2013; 28(1):49-58. PubMed ID: 23314530
[TBL] [Abstract][Full Text] [Related]
4. Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections.
Finney MS; Crank CW; Segreti J
Curr Med Res Opin; 2005 Dec; 21(12):1923-6. PubMed ID: 16368041
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of Corynebacterium striatum endocarditis with daptomycin plus rifampin.
Shah M; Murillo JL
Ann Pharmacother; 2005 Oct; 39(10):1741-4. PubMed ID: 16144879
[TBL] [Abstract][Full Text] [Related]
6. Daptomycin: a review 4 years after first approval.
Sauermann R; Rothenburger M; Graninger W; Joukhadar C
Pharmacology; 2008; 81(2):79-91. PubMed ID: 17940348
[TBL] [Abstract][Full Text] [Related]
7. Moderate liver impairment has no influence on daptomycin pharmacokinetics.
Dvorchik B
J Clin Pharmacol; 2004 Jul; 44(7):715-22. PubMed ID: 15199076
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical experience with daptomycin.
Hawkey PM
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii7-14. PubMed ID: 18829726
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.
Benvenuto M; Benziger DP; Yankelev S; Vigliani G
Antimicrob Agents Chemother; 2006 Oct; 50(10):3245-9. PubMed ID: 17005801
[TBL] [Abstract][Full Text] [Related]
10. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
11. Daptomycin, a lipopeptide antibiotic in clinical practice.
Weis F; Beiras-Fernandez A; Schelling G
Curr Opin Investig Drugs; 2008 Aug; 9(8):879-84. PubMed ID: 18666036
[TBL] [Abstract][Full Text] [Related]
12. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin.
Mohan SS; McDermott BP; Cunha BA
Heart Lung; 2005; 34(1):69-71. PubMed ID: 15647736
[TBL] [Abstract][Full Text] [Related]
13. Gemfibrozil-induced myositis in a patient with normal renal function.
Hahn M; Sriharan K; McFarland MS
Ann Pharmacother; 2010 Jan; 44(1):211-4. PubMed ID: 19934390
[TBL] [Abstract][Full Text] [Related]
14. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
[TBL] [Abstract][Full Text] [Related]
15. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
[TBL] [Abstract][Full Text] [Related]
16. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program.
Figueroa DA; Mangini E; Amodio-Groton M; Vardianos B; Melchert A; Fana C; Wehbeh W; Urban CM; Segal-Maurer S
Clin Infect Dis; 2009 Jul; 49(2):177-80. PubMed ID: 19500039
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
18. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC
Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384
[TBL] [Abstract][Full Text] [Related]
19. Colchicine myotoxicity: case reports and literature review.
Wilbur K; Makowsky M
Pharmacotherapy; 2004 Dec; 24(12):1784-92. PubMed ID: 15585444
[TBL] [Abstract][Full Text] [Related]
20. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
Steenbergen JN; Alder J; Thorne GM; Tally FP
J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
